Kowa Pharmaceutical Europe Co. Ltd. (KPE) regularly receives requests for monetary grants to support a range of activities by professional healthcare organisations. These unrestricted grants are provided to support such activities as research where Kowa is not directly involved, Independent Medical Education Programmes or attendance of the organisations healthcare professionals at medical or scientific meetings where it may be used to cover expenses.
KPE does not solicit requests for grants nor does it get involved in the detail of how the grant is used, we do however ensure that it is for a valid purpose to benefit either patients or public health.
Payments to healthcare professionals and healthcare organisations:
Healthcare professionals (HCPs) and Healthcare organisations (HCOs) provide a number of services to KPE, based on their clinical knowledge or knowledge of healthcare systems and healthcare management.
These services are provided through a number of means:
Advisory boards: Where they join with other experts in a particular field to provide insight and direction to our research activities helping us to ensure we are able to develop products that provide benefit to patients or satisfy an unmet clinical need.
Symposia speaker services: KPE provides a number of educational speaker services at symposia and congresses where HCP/HCOs are invited to speak either on a therapy area relevant to our company or to inform HCP/HCOs of recent scientific findings related to a Kowa product. Reimbursement for these services accurately reflects the experience of the HCP/HCO as well as the time and effort contributed by the HCP/HCO and conforms to local guidelines.
The payments made by KPE are in respect of products currently or soon to be marketed. For pipeline products payments are made by Kowa Research Europe Ltd. (KRE) a sister company in the group.
Support provided is never an inducement to either prescribe or reward prescription of our products and we make every effort to ensure that the HCPs and HCOs are transparent about our support both to their colleagues and to their employers.
Since 2013 Kowa Pharmaceutical Europe Co. Ltd. (KPE), in line with transparency and best practice, has reported the total amount paid to healthcare professionals in fees for consultancy services received. Each year the total amount paid for the previous calendar year is reported, as well as the number of UK healthcare professionals that received such payments. In 2016 this was extended to capture all payments made to both HCPs and HCOs within Europe.
|Total KPE amount paid in 2017 to HCPs||No. of HCP's*||Total KPE amount paid in 2017 to HCOs||No. of HCO's*|
|Total payments made by KPE||£7,051.84||4**||£442.48||1**|
|Attendance & Participation to Ad Board||£0.00||0||£0.00||0|
|Attendance & Participation to Speaker Meeting / Congress Symposium||£2,750.00||2||£0.00||0|
|Other Consultancy (inc Travel, Accommodation, Donations & Grants)||£4,301.84||4||£442.48||1|
|Total KRE amount paid in 2017 to HCPs||No. of HCP's*||Total KRE amount paid in 2017 to HCOs||No. of HCO's*|
|Total payments made by KRE||£12,701.70||4**||£0.00||0**|
|Attendance & Participation to Ad Board||£0.00||0||£0.00||0|
|Attendance & Participation to Speaker Meeting / Congress Symposium||£4,500.00||4||£0.00||0|
|Other Consultancy (inc Travel, Accommodation, Donations & Grants)||£8,201.70||3||£0.00||0|
* Some individual HCPs/HCOs may have engaged several times for each consultancy activity. These HCPs will only be counted once in each activity
** Some individual HCPs/HCOs may have engaged for multiple types of consultancy activities, e.g. participation at Advisory Board and participation at a Speaker Meeting. These HCPs/HCOs will only be counted once in this total.
Payments made by Kowa Pharmaceutical Europe Co. Ltd. (KPE) to European Healthcare Professionals in 2016 totalled £16,991.95 and payments to Healthcare Organisations totalled £5,254.96. Payments made by Kowa Research Europe Ltd. (KRE) to European Healthcare Professionals in 2016 totalled £8,839.66 and payments to Healthcare Organisations totalled £7,719.36.
Payments made by Kowa Pharmaceutical Europe Co. Ltd. (KPE) to UK Healthcare Professional in 2015 totalled £11,662.53 for providing advice and consultancy, including chairing and speaking at meetings, and participation in advisory boards.
Payments made by Kowa Pharmaceutical Europe Co. Ltd. (KPE) to UK Healthcare Professional in 2014 totalled £37,765 for providing advice and consultancy, including chairing and speaking at meetings, and participation in advisory boards.
Payments made by Kowa Pharmaceutical Europe Co. Ltd. (KPE) to UK Healthcare Professional in 2013 totalled £8,681 for providing advice and consultancy, including chairing and speaking at meetings, and participation in advisory boards.
KPE ensures that any payment made to HCPs is reasonable, within market rates and reflects the time they spend speaking / advising.
Hospitality and promotional expenditure:
In the course of our usual business we must interact with HCPs and provide in some instances hospitality. This hospitality and these interactions are highly regulated and are governed by the local Marketing Code of Practice. We commit that our promotional practices are ethical and in line with UK and European marketing codes and that we will not enter into any promotional activity for unapproved medicines or for unapproved uses of our medicines. Our business practices prohibit the offering of any bribe, kick back or inducement to any government official or any other person in return for a service.
The Bribery Act 2011:
KPE requires that all of its staff and those of third parties acting on its behalf comply with all anti-corruption legislation and act with the highest ethical standards. Payments or acts that create the impression that a received service will receive a payment in kind are not tolerated. All existing agreements with partner organisations are reviewed and updated to ensure that they comply with the anti-bribery and corruption legislation. Particular efforts are focussed on ensuring that any activities carried out by staff of KPE or partner organisations in high risk markets are reviewed on a regular basis and a process is put in place whereby any staff who have concerns can raise it with senior management in a confidential manner. Regular reviews of partner organisations anti-bribery policies will take place to ensure they fully support the UK Bribery Act and the US Foreign Corrupt Practices Act as well as any other relevant anti-corruption laws.
UIN: KPE18 00002a
Date of Prep: June 2018